Janssen has submitted two Marketing Authorisation Applications to the EMA for an investigational Ebola vaccine regimen.
List view / Grid view
Filter the results
Janssen has recently received marketing authorisation from the European Commission for Stelara to treat ulcerative colitis. Dr Jaime Oliver discusses the mode of action and why the treatment is needed.
500,000 regimens of Janssen's investigational Ebola vaccine are to be donated to support the Ebola outbreak response in the Democratic Republic of the Congo.
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.
The FDA has awarded a breakthrough therapy designation to an investigational prophylactic vaccine to treat respiratory syncytial virus in seniors.
The pharmaceutical company is planning to appeal the decision to pay the state for damages relating to the US opioid crisis.
Five pharma companies have filed a complaint in Canadian court over new rules intended to lower the price of drugs in the country.
The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.
Modernisation of microbiological test methods involves far more than just the science. As new systems and technologies become available it becomes increasingly important that potential users can identify not only the technical requirements, but also the business case. Here, Paul Newby, Alice Laures and Lisa Wysocki from GlaxoSmithKline discuss criteria…
The FDA has approved the first ever non-chemotherapy combination treatment using ibrutinib and obinutuzumab for the most common form of adult leukaemia...